文献速递肝胆胰外科围术期管理与 ERAS

胰腺切除术后肝损伤:肝血管切除时代的重要临床实体

Postpancreatectomy liver injury: A relevant entity in the modern era of pancreatic cancer surgery with hepatic vessel resection. A monocentric retrospective cohort study.
PubMed 文献 · Surgery · 2026-05-02

单中心回顾性队列研究分析116例胰腺切除联合肝血管切除患者,13%发生临床相关术后肝损伤,该组死亡率显著增高(47% vs 3%)。术后48小时内肝动脉阻力指数降低及乳酸、胆红素、转氨酶升高与肝损伤相关,联合血管切除和ALT峰值>1680 U/L为独立关联因素。

要点

  • 胰腺切除联合肝血管切除后临床相关肝损伤发生率为13%,死亡率达47%。
  • 术后48小时内肝动脉阻力指数降低及转氨酶、胆红素、乳酸升高提示肝损伤。
  • 联合门静脉/肠系膜上静脉+腹腔干/肝动脉切除及ALT峰值>1680 U/L与肝损伤独立相关。

核心结论

  • 临床相关胰腺切除术后肝损伤与显著死亡率相关。
  • 术后48小时内低阻力指数和显著升高的生化标志物与临床相关肝损伤相关,可用于触发早期干预。

研究设计与样本

  • 单中心回顾性队列研究,纳入116例胰腺切除联合肝血管切除(门静脉/肠系膜上静脉、腹腔干、肝动脉)患者。
  • 术后评估动脉乳酸、总胆红素、丙氨酸氨基转移酶、天冬氨酸氨基转移酶、国际标准化比值及多普勒超声阻力指数,随访至术后90天。

主要发现

  • 116例中15例(13%)发生临床相关胰腺切除术后肝损伤。
  • 临床相关肝损伤组死亡率显著高于无肝损伤组(47% vs 3%;P < .001)。
  • 临床相关肝损伤组肝固有动脉阻力指数较低(0.52 vs 0.65;P = .034)。
  • 临床相关肝损伤组术后48小时峰值乳酸、胆红素、天冬氨酸氨基转移酶和丙氨酸氨基转移酶均显著升高(均P < .01)。

关键数值与推荐

  • 临床相关胰腺切除术后肝损伤定义为美国肝病研究学会定义的肝衰竭和/或需要对肝脏并发症进行侵入性治疗。
  • 多变量分析中,联合门静脉/肠系膜上静脉+腹腔干/肝动脉切除和丙氨酸氨基转移酶48小时峰值>1680 U/L与临床相关肝损伤发生显著相关。

临床怎么用

  • 术后48小时内监测肝动脉阻力指数及乳酸、胆红素、转氨酶,有助于识别临床相关肝损伤高风险患者。
  • 对联合血管切除及ALT峰值>1680 U/L者应警惕肝损伤,考虑早期干预。

局限性

  • 单中心回顾性研究,样本量有限(116例),结论需外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Advances in pancreatic cancer surgery involve hepatotoxic chemotherapies and hepatic vasculature resections, increasing the risk of clinically relevant postpancreatectomy liver injury. The study aimed to analyze the incidence and impact of clinically relevant postpancreatectomy liver injury after pancreatectomy with hepatic vessel resection. METHODS: In this single-institutional study, patients undergoing pancreatectomy with resection of hepatic vessels (portal vein/superior mesenteric vein, celiac axis, and hepatic arteries) were analyzed. Arterial lactate, total bilirubin, alanine aminotransferase, aspartate aminotransferase, international normalized ratio, and Doppler ultrasound-derived resistive index were assessed postoperatively. Postoperative outcomes were assessed through 90 days. Clinically relevant postpancreatectomy liver injury was defined as American Association for the Study of Liver Diseases-defined liver failure and/or need for invasive treatment of liver complications. RESULTS: Among 116 patients (67% portal vein/superior mesenteric vein resection alone, 7% celiac axis/hepatic arteries alone, 26% portal vein/superior mesenteric vein + celiac axis/hepatic artery resection), 15 (13%) developed clinically relevant postpancreatectomy liver injury. Mortality was significantly higher in the clinically relevant postpancreatectomy liver injury group (47% vs 3%; P < .001). The proper hepatic artery resistive index was lower in the clinically relevant postpancreatectomy liver injury group (0.52 vs 0.65; P = .034), whereas the following 48-hour-peak blood tests were significantly higher in this group: Lac, bilirubin, aspartate aminotransferase, and alanine aminotransferase (all P < .01). Combined portal vein/superior mesenteric vein + celiac axis/hepatic arteries and elevated alanine aminotransferase 48-hour peak above 1680 U/L remained significantly associated with the occurrence of clinically relevant postpancreatectomy liver injury in multivariable analyses. Forty percent of clinically relevant postpancreatectomy liver injury occurred in the absence of vascular complications. CONCLUSION: Clinically relevant postpancreatectomy liver injury is associated with significant mortality. Low resistive index and markedly elevated biochemical markers within the first 48 hours correlate with clinically relevant postpancreatectomy liver injury and may be used to trigger earlier intervention. Given the associated morbidity and mortality, defining, preventing, and mitigating clinically significant postpancreatectomy liver injury is of the utmost importance.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Marchetti A, Salinas CH, Garnier J, et al. Postpancreatectomy liver injury: A relevant entity in the modern era of pancreatic cancer surgery with hepatic vessel resection. A monocentric retrospective cohort study. Surgery. 2026. PMID: 42173064. doi:10.1016/j.surg.2026.110302

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。